Introduction
The adequate supply of oxygen and nutrients is essential for proper tissue function and survival. During evolution, blood vessels arose to fulfil these fundamental tasks of life. Not surprisingly, the integrity of the vascular system is crucial also for repair of injured tissue, and the imbalance in growth and/or preservation of blood vessels contribute to the pathogenesis of numerous diseases.
In 1997, Asahara et al. described human peripheral blood cells that differentiate into mature endothelial cells and form new blood vessels in vivo [2] . Until then, it was thought that postnatal formation of blood vessels results exclusively from proliferation and remodelling of the pre-existing vascular network, a process referred to as angiogenesis. After this first report, many laboratories published their findings on identification and isolation of circulating primitive endothelial precursors or endothelial progenitor cells (EPCs) that participate in vasculogenesis, i.e. the de novo formation of blood vessels. Meanwhile, the role of EPCs in vascular and tissue regeneration and their therapeutic prospective in regenerative medicine has been intensively studied.
Characterization and isolation of EPCs
In their landmark paper, Asahara et al. found that peripheral blood mononuclear cells enriched for CD34+-expressing cells could differentiate into endothelial-like cells [2] . After 7 days in culture on fibronectin, the majority of these cells expressed the endothelial cell surface markers CD31 and/or Tie-2, i.e. vascular endothelial growth factor (VEGF) receptor [2] . They also expressed endothelial nitric oxide synthase (eNOS) mRNA and produced NO after stimulation with VEGF or acetylcholine in a dose-dependent manner. In addition, they took up acetylated low-density lipoprotein (acLDL), bound Ulex lectin and formed tube-like structures in vitro. Thus, these cultured CD34+-enriched cells exhibited multiple antigenic and functional properties that are typical for endothelial cells [2] . However, in many subsequent studies, conflicting results on identification and characterization of EPCs were reported due to the lack of a unique marker to identify EPCs, their paucity in the circulation and, most importantly, due to their phenotypic and functional overlap with haematopoietic and mature endothelial cells. Several studies revealed that many blood cells express the putative endothelial cell antigens CD31 and Tie-2, and that there is a considerable overlap in the endothelial cell/monocyte phenotype. Moreover, monocytes also bind Ulex lectin and take up acLDL, and inherently express CD31, CD105 or CD144, making them almost phenotypically indistinguishable from endothelial cells [22] . So far, the only property identified to be specific for endothelial cells is the expression of eNOS and release of NO in response to physiologic stimuli [1, 2, 19] .
Several assays were developed to isolate EPCs from peripheral blood mononuclear cells. Two major cell types were harvested from these assays, the so-called early-outgrowth EPCs and the late-outgrowth EPCs, according to their timedependent appearance in culture, and to other features such as cell surface markers, proliferation rate and function [25] . However, virtually all available experimental data is limited to early outgrowth EPCs, i.e. cultured spindle-shaped cells obtained from peripheral blood mononuclear cells as originally described by Asahara et al. [2] , because the vast majority of laboratories used them in their experiments and because of absence of in vivo studies showing significant vasculogenesis and/or tissue regeneration by late-outgrowth EPCs. All later mentioned studies refer therefore on earlyoutgrowth EPCs.
Mechanisms of neovascularization by EPCs
The mechanism by which EPCs mediate neovascularization was initially thought to be differentiation into endothelial cells and direct incorporation into newly formed vessels. However, in studies using different animal tissue injury models, only marginal EPC incorporation into the vasculature was found in neo-vascularized tissue that was analysed weeks (!) after the initial injury. Based on these results, the idea that EPCs stimulate neovascularization via paracrine effects gained increasing attention [27] . Although the question how EPCs actually enhance neovascularization is still not resolved, results from experimental studies indicate that EPCs may be used as disease or prognostic marker or for therapeutic implications, e.g. for blood vessel and renal tissue regeneration.
EPCs in chronic kidney disease
Recent experimental and clinical data indicate that EPCs may become incompetent in their ability to regenerate ischaemic tissue thereby contributing to increased morbidity of patients with cardiovascular risk factors such as hypertension or diabetes. Indeed, these patients exhibit significantly lower numbers of circulating EPCs than healthy controls [3, 13, 18] . Moreover, impaired renal function and uraemia result in +AH4-30% decrease of circulating EPCs (Table 1 ). In addition, these EPCs are also malfunctioning [8, 10] . In patients with chronic kidney disease (CKD) stage V receiving haemodialysis therapy, a low level of circulating CD34 cells, i.e. a population including also EPCs, was shown to be an independent predictor for both prevalent cardiovascular events and all-cause mortality [20] .
Several factors present in patients with CKD may have a negative impact on EPC number and function: hypertension, dyslipidaemia, glucose intolerance (even in the absence of frank diabetes), micro-inflammation and increased C-reactive protein (which has a direct effect on EPC number and activity), oxidative stress, low levels of erythropoietin (EPO), known and yet unidentified uraemic toxins etc. The latter is particularly intriguing, since we and others could show that initiation of haemodialysis therapy or successful kidney transplantation improves EPC number and function. Interestingly, kidney graft function directly determines EPC number [12, 24] . In line with the hypothesis that attenuation of the uraemic state restores EPC number and function, at least in part, are results from a recent study by Chan et al. [7] showing that patients on prolonged and more frequent nocturnal haemodialysis (i.e. 6-8 h a night, five to six nights per week) circulating EPCs as significantly higher compared to patients on conventional haemodialysis. Moreover, Choi et al. [8] reported a positive association of dialysis dose (Kt/V) and EPC function, suggesting that more intensive dialysis therapy may improve EPC number and function in CKD patients on renal replacement therapy. In this respect, findings from a recently published study in 67 peritoneal dialysis and 142 haemodialysis patients are of considerable interest [26] . Even after adjusting for several potential confounders such as age, blood pressure, history of cardiovascular disease, presence of diabetes, treatment with drugs that stimulate EPCs etc., their number was significantly higher in patients on peritoneal dialysis as compared to patients on haemodialysis.
Pharmacological modulation of EPCs
Instead of cell therapy with EPCs (i.e. progenitor cell transplantation) that is still hampered by many technical and regulatory obstacles, pharmacological stimulation and/or modulation of EPCs might be more promising in terms of clinical practicability. It is known that physiological mobilization of EPCs from their niches such as the bone marrow can be triggered by mechanical injury and ischaemic stress via generation of hypoxia-inducible factor-1 regulated release of VEGF, EPO, SDF-1 and GM-CSF [4] [5] [6] 11] . With respect to the possibility of their pharmacological mobilization, various drugs like statins [17, 28] , glitazones [23] or insulin [15] have been shown to stimulate EPCs. Studies on drugs that are of special interest for nephrologists such as antihypertensive agents or recombinant human EPO (rHuEPO) are summarized in Table 2 .
The angiotensin-converting enzyme inhibitors ramipril [21] and enalapril [29] were shown to increase EPC levels both in experimental studies and in patients, probably by interfering with the CD26/dipeptidylpeptidase IV system. Similar findings were shown for angiotensin receptor blockers like olmesartan, irbesartan, losartan or telmisartan [5, 14, 30] . The EPO receptor, which main function is to stimulate the proliferation and the differentiation of Cyclosporine A inhibits proliferation, eNOS mRNA expression and nitric oxide production in human EPCs in a dose-dependent manner erythroid precursor cells, is also present on endothelial cells, suggesting a common ontogenesis for the haematopoietic and endothelial lineage. Both rHuEPO as well as its longer lasting derivate darbepoetin alpha significantly enhance the number and functional properties of EPC via the activation of the intracellular Akt protein kinase pathway [4, 5] . Interestingly, this effect was already observed with a dose of 30 IU/kg per week and less, i.e. a dose which does not induce erythropoiesis. Finally, some drugs such as immunosuppressive agents may also negatively affect EPCs since their number was reduced by >40% with addition of prednisolone or cyclosporine A in concentrations corresponding to the usual daily therapeutic doses into the cell culture media [9, 16] .
Conclusion
While stem cell therapy for tissue regeneration after kidney injury is currently tested in numerous pre-clinical (animal) studies, EPCs have attracted less attention so far. Most data available support the notion that EPC numbers and function are reduced in CKD patients, and this altered EPC biology may contribute to the high cardiovascular burden of CKD patients due to compromised reparative processes in the vascular system. EPC monitoring might be useful for the clinician as a prognostic marker. Early targeted pharmacological therapy in order to improve EPC number and function in CKD patients might therefore be of interest in order to improve cardiovascular outcome in this population.
